- Home
- LUCY vs CNSP Comparison
LUCY vs CNSP Comparison
Compare LUCY & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | CNSP |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 8.5M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LUCY | CNSP |
|---|---|---|
| Price | $0.83 | $3.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 114.5K | 16.9K |
| Earning Date | 11-20-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.39 | 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,661,669.00 | N/A |
| Revenue This Year | $170.51 | N/A |
| Revenue Next Year | $205.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 62.65 | N/A |
| 52 Week Low | $0.65 | $1.90 |
| 52 Week High | $2.02 | $10.54 |
Technical Indicators
Market Signals| Indicator | LUCY | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 34.89 |
| Support Level | $0.78 | $2.01 |
| Resistance Level | $0.89 | $4.00 |
| Average True Range (ATR) | 0.06 | 0.64 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 52.01 | 12.57 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.